Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.31
29/10/2025 11:00
Oct 29 (Reuters) - Fulcrum Therapeutics Q3 operating expenses USD 21.858 million. Q3 operating income USD -21.858 million vs. IBES estimate USD -20.6 million Q3 net income USD -19.595 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program